SurVaxM appeared to be safe and well-tolerated in pts with nGBM. SurVaxM was effective at stimulating survivin-specific immune responses and the primary endpoint was met.

First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center is the first center to treat patients…